IL-12和TRAIL在肿瘤治疗中的作用  

The Role of IL-12 and TRAIL in Tumor Treatment

作　　者：闫寒梅 赵悦荣 王为光[1] 张纯[2] YAN Han-mei;ZHAO Yue-rong;WANG Wei-guang;ZHANG Chun(Jiamusi University,Jiamusi 154007,Heilongjiang,China;Department of Hematology,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002,Heilongjiang,China)

机构地区：[1]佳木斯大学,黑龙江佳木斯154007 [2]佳木斯大学附属第一医院血液科,黑龙江佳木斯154002

出　　处：《医学信息》2020年第24期49-52,共4页Journal of Medical Information

摘　　要：白介素-12(IL-12)及肿瘤坏死因子相关凋亡配体(TRAIL)均是具有抗肿瘤作用的细胞因子,其中IL-12是一种通过激活T细胞和巨噬细胞以杀死肿瘤细胞的蛋白质,由p35和p40两条多肽链通过二硫键聚合而成;而TRAIL是肿瘤坏死因子超家族成员之一,由于受体的分布情况不同,导致其可以选择性地杀伤肿瘤细胞,而对正常细胞没有显著的细胞毒性。本文就IL-12及TRAIL的结构、生物学功能及二者在肿瘤治疗中的作用作一综述,以期为临床治疗提供参考。Interleukin-12(IL-12)and tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)are cytokines with anti-tumor effects.IL-12 is a protein that kills tumor cells by activating T cells and macrophages.It is formed by the polymerization of two polypeptide chains p35 and p40 through disulfide bonds;TRAIL is a member of the tumor necrosis factor superfamily.The distribution of receptors is different,leading to their selective killing of tumor cells without significant cytotoxicity to normal cells.This article reviews the structure and biological functions of IL-12 and TRAIL and their roles in tumor treatment,in order to provide references for clinical treatment.

关 键 词：IL-12 TRAIL 肿瘤 

分 类 号：R73[医药卫生—肿瘤]